CTMX - Company ID 0001501989
The table below shows CytomX Therapeutics, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $76.20M | $138.10M | $101.21M | $53.16M | $37.31M | $68.43M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $68.73M | $83.38M | $77.68M | $111.65M | $114.19M | $112.94M |
| SG&A |
CytomX Therapeutics, Inc. reported annual revenue of $76.20M for fiscal year 2025. That is down 44.8% from $138.10M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $15.04M (FY 2016) to $76.20M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $29.84M |
| $29.73M |
| $30.02M |
| $42.85M |
| $39.16M |
| $36.03M |
| Operating income | -$22.36M | $25.00M | -$6.48M | -$101.33M | -$116.04M | -$80.54M |
| Income tax | $238.00K | $224.00K | $3.89M | $0.00 | $0.00 | -$13.91M |
| Net income | -$17.37M | $31.87M | -$569.00K | -$99.32M | -$115.87M | -$64.82M |
| EPS (diluted) | - | - | - | - | - | - |